BCAL Diagnostics Limited (ASX:BDX) has notified the market of the issue of 1,000,000 unquoted convertible notes (ASX security code: BDXAI) at an issue price of A$1.00 per security, with the securities issued on 17 November 2026 as part of a convertible note facility previously announced to the market.

Key Points

  • 1,000,000 convertible notes (BDXAI) were issued on 17 November 2026 at A$1.00 each, raising A$1,000,000 in cash consideration in Australian dollars.
  • The securities are unquoted and are not intended to be quoted on ASX.
  • The issue forms part of a transaction previously announced via an Appendix 3B dated 21 August 2026.
  • Further drawdowns under the convertible note facility are yet to take place to complete the transaction.
  • Following the issue, total BDXAI convertible notes on issue stand at 8,600,000.

Convertible Note Issue Terms

According to the filing, BCAL Diagnostics issued 1,000,000 convertible notes under the ASX security code BDXAI on 17 November 2026. The securities were issued for a cash consideration of A$1.00 per security, payable in Australian dollars. The convertible notes are classified as unquoted securities and are not intended to be listed or traded on ASX. The notification was submitted as an Appendix 3G on 18 November 2026, confirming the issue as a new announcement.

Transaction Background and Further Drawdowns

The filing states that the convertible note issue forms part of a placement or other type of issue that was previously notified to the market in an Appendix 3B, lodged on 21 August 2026. The company disclosed that further issues of securities are yet to take place to complete the transaction, with the filing specifically identifying further drawdowns under the convertible note facility as the remaining component. No additional details regarding the terms or timing of those further drawdowns were disclosed in this filing.

Securities on Issue Following the Transaction

Following the issue of the convertible notes, BCAL Diagnostics' total quoted ordinary fully paid shares (ASX:BDX) stand at 370,067,041. Among unquoted securities, the company holds 8,600,000 BDXAI convertible notes on issue, 2,082,917 BDXAF performance rights, 3,467,353 BDXAD options expiring 20 November 2029 with an exercise price of $0.0574, and 12,000,000 BDXAH options expiring 8 October 2027 with an exercise price of $0.25. The filing noted that the automatically generated figures may not reflect current issued capital if other forms are simultaneously being processed by ASX.